Janux Therapeutics, Inc. - Common Stock — Liquidità Trimestrale (NASDAQ:JANX) | MetaTrader

Apri il grafico completo Full chart

Financials

Panoramica Estratto Conto Statistiche

Trimestrale Annuale

Totale attivo 1.06 B1.05 B1.03 B1.02 B1 B1.03 B Totale passività 38.73 M38.3 M41.7 M48.21 M44.74 M86.69 M Patrimonio netto totale 1.02 B1.01 B990.52 M976.55 M956.82 M941.53 M Totale passività e patrimonio netto 1.06 B1.05 B1.03 B1.02 B1 B1.03 B Debito totale —————— Indebitamento netto ——————

Notizie

Wall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's What You Should Know

Here's Why You Should Add JANX Stock to Your Portfolio Now

La VP di Janux Therapeutics Maria Dobek vende azioni per $28.878

Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimates

How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44%

Undercovered Stocks: Western Digital, SAP, Toast And More

Janux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash Value (JANX)

BofA riduce il target su Janux Therapeutics per modifiche alla pipeline

Janux interrompe lo sviluppo della terapia oncologica mirata a EGFR

Bristol-Myers Squibb: 'Strong Buy' As 2026 Milestones Could Bolster Its Prospects (NYSE:BMY)

H.C. Wainwright conferma il rating buy su Janux Therapeutics

Will Acute Care Strength Help Universal Health Offset Q1 Rising Costs?